We are live on ! Find out more
DNTH icon

Dianthus Therapeutics
DNTH

70 hedge funds and large institutions have $419M invested in Dianthus Therapeutics in 2019 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 25 increasing their positions, 10 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 10

113% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 8

11% more funds holding

Funds holding: 63 → 70 (+7)

3% more capital invested

Capital invested by funds: $406M → $419M (+$12.6M)

0.09% less ownership

Funds ownership: 4.62% → 4.53% (-0.09%)

50% less funds holding in top 10

Funds holding in top 10: 4 → 2 (-2)

Holders
70
Holders Change
+7
Holders Change %
+11.11%
% of All Funds
1.52%
Holding in Top 10
2
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
17
Increased
25
Reduced
10
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
GGHC
Gilder Gagnon Howe & Co
New York
+$36.2M
2
BlackRock
BlackRock
New York
+$7.54M
3
EAM
Eventide Asset Management
Massachusetts
+$6.57M
4
Alkeon Capital Management
Alkeon Capital Management
New York
+$6.18M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$5.87M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$21M
2
AG
Artal Group
Luxembourg
-$2.73M
3
Invesco
Invesco
Georgia
-$880K
4
BCM
Bridgeway Capital Management
Texas
-$691K
5
SIM
Spark Investment Management
New York
-$408K
Name Holding Trade Value Shares
Change 		Change in
Stake
TGI
1
TRV GP IV
Massachusetts
$118M – – –
GGHC
2
Gilder Gagnon Howe & Co
New York
$61.6M +$36.2M +146,485 +128%
EAM
3
Eventide Asset Management
Massachusetts
$50.8M +$6.57M +26,562 +14%
AI
4
Alphabet Inc
California
$49.3M – – –
CC
5
Casdin Capital
New York
$44.3M +$5.56M +22,488 +14%
BlackRock
6
BlackRock
New York
$23.9M +$7.54M +30,504 +43%
Vanguard Group
7
Vanguard Group
Pennsylvania
$13M +$5.87M +23,759 +75%
OM
8
Opaleye Management
Massachusetts
$7.89M +$386K +1,563 +5%
Alkeon Capital Management
9
Alkeon Capital Management
New York
$5.9M +$6.18M +25,000 New
HMC
10
Harvard Management Company
Massachusetts
$4.91M – – –
State Street
11
State Street
Massachusetts
$4.08M +$1.92M +7,777 +82%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$3.54M +$1.84M +7,459 +99%
Bessemer Group
13
Bessemer Group
New Jersey
$3.5M – – –
Principal Financial Group
14
Principal Financial Group
Iowa
$3.44M -$35.4K -143 -1%
Citadel Advisors
15
Citadel Advisors
Florida
$3.38M +$848K +3,428 +31%
PIM
16
Platinum Investment Management
Australia
$3.34M +$250K +1,013 +8%
Northern Trust
17
Northern Trust
Illinois
$2.7M +$411K +1,663 +17%
LCM
18
Laurion Capital Management
New York
$2.12M +$2.05M +8,282 +1,200%
Fidelity Investments
19
Fidelity Investments
Massachusetts
$1.8M +$1.89M +7,644 New
AA
20
ALPS Advisors
Colorado
$1.19M +$1.25M +5,042 New
BCM
21
Bridgeway Capital Management
Texas
$815K -$691K -2,795 -45%
N
22
Nuveen
North Carolina
$785K +$822K +3,326 New
Bank of New York Mellon
23
Bank of New York Mellon
New York
$781K +$154K +624 +23%
Charles Schwab
24
Charles Schwab
California
$638K +$173K +700 +35%
BCM
25
BlueCrest Capital Management
Jersey
$590K +$155K +625 +33%
1
2 3 4

DNTH Hedge Fund Activity: Q2 2019 in Review

70 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q2 2019, worth a combined $419M — up 3.1% from $406M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new DNTH positions and 8 closed out — a net gain of 9 holders — while 25 added to existing stakes and 10 trimmed.

The largest buyer was Gilder Gagnon Howe & Co, adding an estimated $36.2M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $21M sold.

  • 70 institutional investors held Dianthus Therapeutics (DNTH) as of Q2 2019, up from 63 in Q1 2019.
  • Funds reported $419M of Dianthus Therapeutics stock for Q2 2019, up 3.1% quarter-over-quarter.
  • 17 funds opened new Dianthus Therapeutics positions in Q2 2019 and 8 closed out, a net change of +9 holders.
  • The largest Dianthus Therapeutics buyer in Q2 2019 was Gilder Gagnon Howe & Co, an estimated $36.2M added.
  • The largest Dianthus Therapeutics seller in Q2 2019 was EcoR1 Capital, an estimated $21M sold.

Based on aggregated 13F filings for Q2 2019.